← Insmed Incorporated (INSM) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Insmed Incorporated (INSM)
Pharmaceutical Preparations · market cap $26.0B · as of 2026-07-10
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-10-29 (est.)
Earnings
Pipeline
18
programs
Upcoming events
2
next 90d+
Dossier
Ready
cached
Insmed Incorporated (INSM) is a pharmaceutical company focused primarily on serious pulmonary and rare diseases, best known for Arikayce (liposomal amikacin for inhalation) targeting NTM lung infection. The company carries a $25.3B market cap despite recurring nine-figure net losses and a cash runway of approximately 7.8 months, with the highest-impact near-term catalyst being a Phase 3 readout for Treprostinil Palmitil Inhalation Powder in pulmonary hypertension expected by end of 2026.
The catalyst path
- 2026-10-29 (est.)Earningsimp 5/10
- 2026-12-31 (est.)Phase 3 · Treprostinil Palmitilimp 9/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| 280 mg Arikayce™ | Phase 2 | Bronchiectasis |
| Liposomal amikacin for inhalation | Phase 3 | Cystic Fibrosis |
| LAI 590 mg | Phase 3 | NTM Lung Infection Due to MAC |
| Cisplatin liposomal | Phase 2 | Osteosarcoma Metastatic |
| Brensocatib 25 mg | Phase 3 | Non-Cystic Fibrosis Bronchiectasis |
| Arikayce™ 560 mg | Phase 2 | Cystic Fibrosis |
| Mometasone furoate nasal spray (MFNS) | Phase 2 | Chronic Rhinosinusitis Without Nasal Polyps |
| Liposomal amikacin for inhalation (Arikayce™) using the PARI Investigational eFlow® Nebulizer. | Phase 3 | Pseudomonas Aeruginosa Infection |
| Treprostinil Palmitil Inhalation Powder | Phase 3 | Pulmonary Hypertension |
| ARIKACE™ | Phase 2 | Cystic Fibrosis |
| Liposomal amikacin for inhalation (LAI) | Phase 2 | Mycobacterium Infections, Nontuberculous |
| Brensocatib | Phase 2 | Hidradenitis Suppurativa |
| Treprostinil Palmitil | Phase 3 | Pulmonary Hypertension |
| Arikayce™ | Phase 2 | Cystic Fibrosis |
| ALIS | Phase 3 | Mycobacterium Infections, Nontuberculous |
| LAI (Liposomal Amikacin for Inhalation) 590 mg | Phase 3 | Mycobacterium Infections, Nontuberculous |
| Brensocatib 10 mg | Phase 3 | Non-Cystic Fibrosis Bronchiectasis |
| rhIGF-I/rhIGFBP-3 | Phase 3 | Myotonic Dystrophy Type 1 |
Price & technical context
3-month
-0.4%
6-month
-31.6%
12-month
-27.3%
52-wk range
$91.88–$211.41
vs 50-day MA
-7.3%
vs 200-day MA
-16.5%
Realized vol
62.9%
Max drawdown
-56.5%
Daily closes through 2026-10-02. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for INSM (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 18 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.